Upstart Holdings, Inc. (UPST)

Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	793.12	635.47	560.43	907.27	801.28	228.6
Other Revenue	91.69	41.5	-11.98	-53.99	50.59	12.84
Revenue	884.81	676.96	548.46	853.29	851.86	241.44
Revenue Growth (YoY)	53.62%	23.43%	-35.72%	0.17%	252.82%	26.63%
Cost of Revenue	166.65	158	150.42	187.99	117.58	37.58
Gross Profit	718.16	518.97	398.04	665.29	734.28	203.86
Selling, General & Admin	476.2	397.74	339.53	531.07	454.89	145.27
Research & Development	258.77	253.65	280.14	237.25	134	38.8
Operating Expenses	734.97	651.39	619.67	768.31	588.89	184.07
Operating Income	-16.82	-132.42	-221.63	-103.02	145.39	19.79
Interest Expense	-36.24	-43.63	-37.99	-13.84	-4.67	-8.03
Interest & Investment Income	18.79	18.79	21.21	9.47	-	0.25
Other Non Operating Income (Expenses)	-5.22	-4.49	-1.61	-1.68	-5.75	-11.36
EBT Excluding Unusual Items	-39.48	-161.76	-240.03	-109.07	134.97	0.65
Merger & Restructuring Charges	-	-	-	-	-1.24	-
Other Unusual Items	33.36	33.36	-	-	-	5.3
Pretax Income	-6.12	-128.4	-240.03	-109.07	133.73	5.95
Income Tax Expense	0.23	0.19	0.11	-0.41	-1.71	0.37
Earnings From Continuing Operations	-6.35	-128.58	-240.13	-108.67	135.44	5.58
Minority Interest in Earnings	-	-	-	-	-	0.4
Net Income	-6.35	-128.58	-240.13	-108.67	135.44	5.98
Preferred Dividends & Other Adjustments	-	-	-	-	-	5.98
Net Income to Common	-6.35	-128.58	-240.13	-108.67	135.44	-
Net Income Growth	-	-	-	-	2163.80%	-
Shares Outstanding (Basic)	93	89	84	83	78	18
Shares Outstanding (Diluted)	93	89	84	83	95	18
Shares Change (YoY)	7.72%	6.79%	1.20%	-12.66%	441.13%	22.17%
EPS (Basic)	-0.07	-1.44	-2.87	-1.31	1.73	-
EPS (Diluted)	-0.07	-1.44	-2.87	-1.31	1.43	-
Free Cash Flow	-65.46	185.49	-113.24	-666.69	159.93	14.34
Free Cash Flow Per Share	-0.70	2.07	-1.35	-8.05	1.69	0.82
Gross Margin	81.16%	76.66%	72.57%	77.97%	86.20%	84.44%
Operating Margin	-1.90%	-19.56%	-40.41%	-12.07%	17.07%	8.20%
Profit Margin	-0.72%	-18.99%	-43.78%	-12.73%	15.90%	-
Free Cash Flow Margin	-7.40%	27.40%	-20.65%	-78.13%	18.77%	5.94%
EBITDA	5.52	-111.87	-196.73	-89.51	152.93	22.07
EBITDA Margin	0.62%	-16.53%	-35.87%	-10.49%	17.95%	9.14%
D&A For EBITDA	22.33	20.55	24.9	13.51	7.54	2.28
EBIT	-16.82	-132.42	-221.63	-103.02	145.39	19.79
EBIT Margin	-1.90%	-19.56%	-40.41%	-12.07%	17.07%	8.20%
Effective Tax Rate	-	-	-	-	-	6.24%
Revenue as Reported	636.53	636.53	513.56	842.44	848.59	233.42

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q